Sorafenib vs. half dose Sorafenib and UFT combined therapy in patients with Hepatocellular carcinoma refractory to TACE: Randomised Prospective Study.
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2014
Price : $35 *
At a glance
- Drugs Sorafenib (Primary) ; Tegafur/uracil (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 13 Feb 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
- 18 Dec 2013 Additional lead trial centre/investigator identified as reported by University Hospital Medical Information Network - Japan record.
- 11 Dec 2013 New trial record